Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Norbert Gattermann; Carlo Finelli; Matteo Della Porta; Pierre Fenaux; Arnold Ganser; Agnes Guerci-Bresler; Mathias Schmid; Kerry Taylor; Dominique Vassilieff; Dany Habr; Gabor Domokos; Bernard Roubert; Christian Schack Rose; EPIC study investigators; Lars Kjeldsen

doi:10.1016/j.leukres.2010.03.009

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Norbert Gattermann, Carlo Finelli, Matteo Della Porta, Pierre Fenaux, Arnold Ganser, Agnes Guerci-Bresler, Mathias Schmid, Kerry Taylor, Dominique Vassilieff, Dany Habr, Gabor Domokos, Bernard Roubert, Christian Schack Rose, EPIC study investigators, Lars Kjeldsen

164 Citationer (Scopus)

Abstract

The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500ng/mL, approximately 50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p

Originalsprog	Engelsk
Tidsskrift	Leukemia Research
Vol/bind	34
Udgave nummer	9
Sider (fra-til)	1143-50
Antal sider	8
ISSN	0261-474X
DOI	https://doi.org/10.1016/j.leukres.2010.03.009
Status	Udgivet - 1 sep. 2010

Adgang til dokumentet

10.1016/j.leukres.2010.03.009

Citationsformater

Gattermann, N., Finelli, C., Porta, M. D., Fenaux, P., Ganser, A., Guerci-Bresler, A., Schmid, M., Taylor, K., Vassilieff, D., Habr, D., Domokos, G., Roubert, B., Rose, C. S., EPIC study investigators, & Kjeldsen, L. (2010). Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leukemia Research, 34(9), 1143-50. https://doi.org/10.1016/j.leukres.2010.03.009

Gattermann, N, Finelli, C, Porta, MD, Fenaux, P, Ganser, A, Guerci-Bresler, A, Schmid, M, Taylor, K, Vassilieff, D, Habr, D, Domokos, G, Roubert, B, Rose, CS, EPIC study investigators & Kjeldsen, L 2010, 'Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study', Leukemia Research, bind 34, nr. 9, s. 1143-50. https://doi.org/10.1016/j.leukres.2010.03.009

@article{9966756591dc4394a759babb0c029fd9,

title = "Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study",

abstract = "The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500ng/mL, approximately 50% were chelation-na{\"i}ve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-na{\"i}ve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p",

author = "Norbert Gattermann and Carlo Finelli and Porta, {Matteo Della} and Pierre Fenaux and Arnold Ganser and Agnes Guerci-Bresler and Mathias Schmid and Kerry Taylor and Dominique Vassilieff and Dany Habr and Gabor Domokos and Bernard Roubert and Rose, {Christian Schack} and {EPIC study investigators} and Lars Kjeldsen",

year = "2010",

month = sep,

day = "1",

doi = "10.1016/j.leukres.2010.03.009",

language = "English",

volume = "34",

pages = "1143--50",

journal = "Leukemia Research",

issn = "0261-474X",

publisher = "Elsevier Limited",

number = "9",

}

TY - JOUR

T1 - Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

AU - Gattermann, Norbert

AU - Finelli, Carlo

AU - Porta, Matteo Della

AU - Fenaux, Pierre

AU - Ganser, Arnold

AU - Guerci-Bresler, Agnes

AU - Schmid, Mathias

AU - Taylor, Kerry

AU - Vassilieff, Dominique

AU - Habr, Dany

AU - Domokos, Gabor

AU - Roubert, Bernard

AU - Rose, Christian Schack

AU - EPIC study investigators

AU - Kjeldsen, Lars

PY - 2010/9/1

Y1 - 2010/9/1

N2 - The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500ng/mL, approximately 50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p

AB - The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500ng/mL, approximately 50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p

U2 - 10.1016/j.leukres.2010.03.009

DO - 10.1016/j.leukres.2010.03.009

M3 - Journal article

C2 - 20451251

SN - 0261-474X

VL - 34

SP - 1143

EP - 1150

JO - Leukemia Research

JF - Leukemia Research

IS - 9

ER -

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater